Aurora Recognized for Executive Gender Diversity by the Globe & Mail for Second Consecutive Year
MWN-AI** Summary
Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) has once again been recognized by The Globe and Mail as a leader in executive gender diversity, earning a spot on the prestigious "Women Lead Here" list for 2026. This recognition marks the second consecutive year that Aurora has been celebrated for its inclusive leadership practices at the executive level.
The Globe and Mail’s "Women Lead Here" benchmark evaluates publicly traded Canadian companies based on their executive leadership teams’ gender diversity. Aurora stands out in the 2026 report with a remarkable 50% of its executive leaders being women, reinforcing the company’s commitment to nurturing a diverse talent pipeline. Lori Schick, Executive Vice President of Human Resources at Aurora, emphasized that this achievement reflects the company’s foundational culture, which prioritizes respect, accountability, and collaboration.
Aurora’s commitment to diversity is not just about meeting numbers; it’s about fostering an environment where female leaders can thrive and have a meaningful impact on the organization and its stakeholders. The company believes that encouraging diverse perspectives enhances overall team effectiveness, ultimately leading to stronger outcomes for their patients and communities.
The "Women Lead Here" list is published in the April 2026 issue of Report on Business magazine, highlighting the progressive strides made by companies like Aurora to promote gender diversity in leadership roles. As a global leader in the medical cannabis sector, Aurora serves various markets, including Canada, Europe, Australia, and New Zealand, maintaining a focus on high-margin opportunities and a patient-first approach.
For more information on Aurora, visit their website or follow them on social media for updates on their ongoing initiatives and corporate developments.
MWN-AI** Analysis
Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) has made headlines again as it earns recognition from The Globe and Mail for executive gender diversity, highlighting its commitment to inclusive leadership. With 50% female leadership at the executive level, Aurora stands out not only in the cannabis industry but also among publicly-traded Canadian companies. This acknowledgment reflects a broader shift toward diversity and inclusion, an essential factor in today’s corporate environment.
From an investment perspective, this recognition could enhance Aurora's reputation among socially conscious investors. There is increasing evidence that companies with diverse leadership teams perform better financially. Aurora's emphasis on fostering women leaders may result in innovative perspectives that drive the company forward, aligning with market expectations for growth dynamics.
Moreover, with a strong focus on patient care and a diverse portfolio of trusted brands, Aurora is well-positioned in the global cannabis market that continues to expand. Given its experience in both medical and consumer segments worldwide, the company holds a potential competitive edge. Investors should consider the long-term implications of Aurora's strategic commitment to inclusivity, which not only tackles societal issues but may also yield positive financial outcomes.
However, stakeholders should remain cautious. Aurora will need to navigate industry challenges such as regulatory hurdles, market saturation, and the competitive landscape. Future performance will also hinge on technical execution and market demand dynamics.
In summary, Aurora Cannabis's recognition for gender diversity underscores its potential as a sustainable investment option. Investors looking for companies prioritizing inclusivity alongside solid growth strategies may find Aurora worthy of consideration, balancing its innovative leadership with vigilant risk assessment.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Aurora Recognized for Executive Gender Diversity by the Globe & Mail for Second Consecutive Year
PR Newswire
NASDAQ | TSX: ACB
The Globe and Mail's Report on Business Women Lead Here List acknowledges Aurora's commitment to inclusive leadership at the executive level
EDMONTON, AB, March 30, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian?based leading global medical cannabis company, has been named on The Globe and Mail's 2026 Report on Business Women Lead Here list for the second consecutive year. The annual editorial benchmark recognizes publicly traded Canadian companies demonstrating strong executive?level gender diversity, underscoring Aurora's continued commitment to inclusive leadership.
"This recognition reflects the culture we've built at Aurora - one grounded in respect, accountability, trust and our deliberate focus on developing a diverse pipeline of female talent," says Lori Schick, Executive Vice President, Human Resources at Aurora. "We've created an environment where female leaders thrive, drive meaningful results and move the business forward in a powerful way - making Aurora a destination for women who want to lead and make an impact."
The Women Lead Here benchmark evaluates executive leadership teams at Canada's largest publicly traded companies using a proprietary, data?driven methodology that prioritizes measurable progress and sustained representation. Aurora is one of 85 companies to appear on this year's list with 50% female executive leadership.
Aurora remains focused on fostering an environment where people are encouraged to contribute meaningfully, lead with compassion and succeed as a team. By fostering collaboration and welcoming diverse perspectives at every level of the organization, the company is enabled to create stronger outcomes for the patients and communities they serve.
The 2026 Women Lead Here list is published in the April 2026 issue of Report on Business magazine, and is available online.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
About The Globe and Mail
The Globe and Mail is Canada's foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With our award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 6.5million readers every week in our print or digital formats, and Report on Business magazine reaches 2.9million readers in print and digital every issue. Our investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family.
Forward Looking Information??
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's ongoing commitment to inclusive leadership and focus on developing a diverse pipeline of female talent, as well as the associated positive impacts for the Company and its patients.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
SOURCE Aurora Cannabis Inc.
FAQ**
How does Aurora Cannabis Inc. ACB plan to maintain its commitment to executive gender diversity in the coming years, especially after being recognized by the Globe & Mail for the second consecutive year?
What specific initiatives has Aurora Cannabis Inc. ACB implemented to develop a diverse pipeline of female talent within the organization that contributed to this recognition?
In what ways can the recognition from the Globe & Mail positively impact Aurora Cannabis Inc. ACB's reputation and employee recruitment efforts in the competitive cannabis industry?
How does Aurora Cannabis Inc. ACB measure the effectiveness and progress of its efforts toward inclusive leadership and executive gender diversity beyond what is reflected in the Globe & Mail's Women Lead Here list?
**MWN-AI FAQ is based on asking OpenAI questions about Aurora Cannabis Inc. (NASDAQ: ACB).
NASDAQ: ACB
ACB Trading
1.3% G/L:
$3.495 Last:
294,372 Volume:
$3.40 Open:
